As highlighted by industry sources, the competition for sites and resources in oncology research is intense, driven by the rapid growth of oncology drugs in development. CRU Hungary stands as a reliable solution to enrollment challenges, offering expertise and efficiency in the increasingly complex landscape of oncology trials.
In the dynamic landscape of early phase oncology studies focusing on solid tumors, efficiency plays a pivotal role at every stage of clinical trial development and implementation. CRU Hungary emerges as a leading force, presenting key advantages that set us apart within the field.
Our Key Advantages
Our commitment to excellence is reflected in the high quality of data we produce, acknowledged and accepted by regulatory bodies such as the FDA, EMA, and others.
CRU Hungary boasts a continuously expanding and easily accessible patient pool across various indications, fueled by the high incidence of cancer indications within Europe and globally. Our proactive recruitment strategies address the challenges of enrolling in oncology trials.
Simple Regulatory Process
We navigate the regulatory landscape seamlessly through the EU Clinical Trials Information System (CTIS), streamlining the approval process for swift trial initiation.
Experienced, Highly Educated Staff
Our team is composed of experienced and highly educated staff, including Principal Investigators (PIs) with over 30 years of study experience in oncology research.
CRU Hungary operates with cutting-edge infrastructure, featuring an in-house trial pharmacy, safety lab, and radiology services (CT, MRI, US, DXA) to support the diverse needs of early phase oncology studies.
Full Site and CRO Services
From initial medical writing to the comprehensive final report, CRU Hungary provides a complete spectrum of Site and Contract Research Organization (CRO) services, ensuring seamless coordination throughout the trial lifecycle.
CRU is a good solution for your enrollment challenges!
Contact CRU Hungary today to explore how we can enhance and expedite your early phase oncology studies for solid tumors.